Private Trust Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Private Trust Company’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59K	Hold	159	–	–	﹤0.01%	2540
2026 Q1	$1.51K	Hold	159	–	–	﹤0.01%	2431
2025 Q4	$1.24K	Hold	159	–	–	﹤0.01%	2404
2025 Q3	$1.21K	Hold	159	–	–	﹤0.01%	2417
2025 Q2	$1.43K	Hold	159	–	–	﹤0.01%	2326
2025 Q1	$1.19K	Buy	+159	New	+$1.28K	﹤0.01%	2338
2023 Q4	–	Sell	-230	Closed	-$1.63K	–	2308
2023 Q3	$1.63K	Hold	230	–	–	﹤0.01%	2146
2023 Q2	$1.62K	Hold	230	–	–	﹤0.01%	2135
2023 Q1	$1.92K	Buy	230 +55	+31%	+$529	﹤0.01%	2088
2022 Q4	$2K	Buy	175 +55	+46%	+$686	﹤0.01%	1991
2022 Q3	$2K	Buy	+120	New	+$1.54K	﹤0.01%	1855

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Private Trust Company's BCRX Position: Q2 2026 in Review

Private Trust Company held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 159 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

Private Trust Company first reported a position in BCRX in Q3 2022 and has held it in 11 quarters since. The position peaked at $2K in Q4 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Private Trust Company held 159 shares of BioCryst Pharmaceuticals worth $1.59K as of Q2 2026.
Private Trust Company left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2540 holding.
Private Trust Company first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
Private Trust Company's BioCryst Pharmaceuticals position peaked at $2K in Q4 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.